Literature DB >> 17996417

Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.

Javier Cobo1, María-Isabel Morosini, Vicente Pintado, Marta Tato, Noemí Samaranch, Fernando Baquero, Rafael Cantón.   

Abstract

We report the use of tigecycline, firstly with colistin and finally alone, in a patient with a persistent breakthrough bacteremia due to a Klebsiella pneumoniae isolate harboring a metallo-beta-lactamase (VIM-1) and an extended-spectrum beta-lactamase (SHV-12). Time-kill studies demonstrated that the combination of both compounds was synergistic along the first 12 h, suppressing the regrowth observed after 3 to 6 h when colistin was tested alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996417     DOI: 10.1016/j.diagmicrobio.2007.09.017

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  17 in total

Review 1.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

Review 2.  New Delhi metallo-β-lactamase-1 in Enterobacteriaceae: emerging resistance.

Authors:  Dylan R Pillai; Allison McGeer; Donald E Low
Journal:  CMAJ       Date:  2011-01-11       Impact factor: 8.262

3.  Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.

Authors:  Paula Virginia Michelon Toledo; Ayrton Alves Aranha Junior; Lavinia Nery Arend; Vanessa Ribeiro; Alexandre Prehn Zavascki; Felipe Francisco Tuon
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

4.  Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.

Authors:  Stéphane Corvec; Ulrika Furustrand Tafin; Bertrand Betrisey; Olivier Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

Review 5.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 6.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  A novel SHV-type beta-lactamase variant (SHV-89) in clinical isolates in China.

Authors:  Jia-Bin Li; Jun Cheng; Qian Wang; Yan Chen; Ying Ye; Xue-Jun Zhang
Journal:  Mol Biol Rep       Date:  2008-06-29       Impact factor: 2.316

8.  Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.

Authors:  George Michail; Maria Labrou; Vassiliki Pitiriga; Styliani Manousaka; Nikolaos Sakellaridis; Athanasios Tsakris; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

Review 9.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

10.  Infections with VIM-1 metallo-{beta}-lactamase-producing enterobacter cloacae and their correlation with clinical outcome.

Authors:  Marco Falcone; Maria Lina Mezzatesta; Mariagrazia Perilli; Chiara Forcella; Alessandra Giordano; Viviana Cafiso; Gianfranco Amicosante; Stefania Stefani; Mario Venditti
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.